Haemonetics Corp (NYSE:HAE)
$ 95.27 -0.46 (-0.48%) Market Cap: 4.84 Bil Enterprise Value: 5.49 Bil PE Ratio: 41.60 PB Ratio: 5.04 GF Score: 84/100

Haemonetics Corp at Raymond James Institutional Investors Conference Transcript

Mar 07, 2022 / 02:50PM GMT
Release Date Price: $59.36 (+1.73%)
Andrew Cooper
Raymond James Financial, Inc. - Analyst

All right. We're about a minute over, so I figure we'd get started. Welcome. I'm Andrew Cooper, the diagnostics and life science tools analyst here at Raymond James. We're happy to have Haemonetics joining us, CEO right here. We've got IR and audience as well. And I'm going to pass it over to Chris to start us off, with just a little bit of an overview, tell us a little bit about who Haemonetics is, and get us rolling this morning.

Christopher Simon
Haemonetics Corporation - Director, President & CEO

Great. Thanks, Andrew, and thank you all for joining. Great to be here. Normal Safe Harbor comments upfront, just to make sure we're all on the same page there in kind of forward-looking views. So when you think about Haemonetics, the company I joined almost six years ago now, I'll kind of articulate what we do and how we approach it in a simple 3 by 3, which is we have three very distinct businesses, what we call plasma, blood center, and hospital. The first two are very much involved in collections,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot